Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$1.87B+76.33%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jose Ignacio Abia Buenache
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 25,258
- Beta
- 1.19
- Country
- ES
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.05
Financials
Revenue
$1.87B+76.3%Net Income
$154.00M+18.0%EBITDA
$535.00M+84.7%Free Cash Flow
$108.00M-55.6%EPS (diluted)
$0.23+21.1%Shares Outstanding (diluted)
680.58M-0.4%Operating Expenses
$375.00MCash & Debt
$529.00MReturn of Capital
$0.00Revenue by Segment (annual)
$7.52BDividend per Share
$0.11Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.23B | $386.13M | $0.57 |
| 2024 | $7.21B | $156.92M | $0.23 |
| 2023 | $6.59B | $42.32M | $0.09 |
| 2022 | $6.06B | $185.03M | $0.31 |
| 2021 | $4.93B | $188.73M | $0.27 |
| 2020 | $5.34B | $618.55M | $0.73 |
| 2019 | $5.10B | $625.15M | $0.95 |
| 2018 | $4.49B | $596.64M | $0.87 |
| 2017 | $4.32B | $662.70M | $0.97 |
| 2016 | $4.05B | $545.46M | $0.80 |
| 2015 | $3.93B | $532.14M | $0.78 |
| 2014 | $3.36B | $470.25M | $0.69 |
| 2013 | $2.74B | $345.55M | $0.51 |
| 2012 | $2.62B | $256.69M | $0.38 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GRFS's reported EPS growth of 3.2% a year over 13 years.
- EPS in 5 years
- $0.66
- Implied price
- $9.30
- Return from $7.40
- 4.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.62 — -37.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -6.8% | -11.6% | -8.3% | -5.5% | -2.9% | -0.6% |
| -1.8% | -6.9% | -3.4% | -0.4% | 2.3% | 4.7% |
| 3.2% | -2.1% | 1.5% | 4.7% | 7.5% | 10.1% |
| 8.2% | 2.6% | 6.4% | 9.7% | 12.7% | 15.4% |
| 13.2% | 7.3% | 11.3% | 14.8% | 17.9% | 20.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-3.85%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·5h ago·Neutral
…better sourcing economics, higher network productivity, and incremental plasma protein revenues, not just revenue growth. Despite a 30%+ EV/EBITDA discount to peers, GRFS's value hinges on operational improvements and cash conversion, not simply low multiples.
View source ↗ - Newszacks.com·8d ago·Neutral
GRFS or SDZNY: Which Is the Better Value Stock Right Now? Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗
Earnings
Tue, Nov 10(in 8 weeks)
Consensus estimate $0.30 per share
Typical surprise -7.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$0.25 vs $0.27miss
- Thu, May 7$0.17 vs $0.16beat
- Thu, Feb 26$0.29 vs $0.29miss
- Tue, Nov 4$0.21 vs $0.24miss
- Tue, Jul 29$0.19 vs $0.23miss
- Mon, May 12$0.13 vs $0.15miss
Estimates and results for GRFS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (17d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Dec 23, 2019 (42d later)Sell$100,001 - $250,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.